Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division. The binding of Tasigna to the BCR-ABL protein blocks the signal that leads to the production of leukemic cells.
Novartis will continue to look to Tasigna to make up for Gleevec’s (imatinib; Novartis) downturn caused by the entry of generic imatinib into the chronic myeloid leukemia (CML) market. The second-generation tyrosine kinase inhibitor (TKI) has displayed cytogenetic and molecular response rates superior to those of Gleevec, but is likely to see its use remain primarily in the second-line setting alongside direct competitor Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka).
LIST OF FIGURES
12 Figure 1: Tasigna for CML – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tasigna for CML
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tasigna for CML
LIST OF TABLES
5 Table 1: Tasigna drug profile
7 Table 2: Tasigna pivotal trial data in CML
9 Table 3: Tasigna late-phase trial data in CML
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.